Pfizer Covid-19 Vaccine | The Business Standard
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
THURSDAY, MAY 26, 2022
THURSDAY, MAY 26, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা

Pfizer Covid-19 Vaccine

A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
Coronavirus chronicle

Pfizer says 3 Covid shots protect children under 5

A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in front of displayed Pfizer logo in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo
Coronavirus chronicle

Pfizer eyes Covid vaccine for all variants before 2023

Photo: Collected
Coronavirus chronicle

Pfizer-BioNTech seek US approval of second Covid booster for 65+

Bangladesh receives 10m more Pfizer doses from US 
Covid-19 in Bangladesh

Bangladesh receives 10m more Pfizer doses from US 

Vials filled with Comirnaty, the Pfizer-BioNTech vaccine against the coronavirus disease (Covid-19), are seen at a vaccination center in St. Stephen's Cathedral, in Vienna, Austria, 5 February, 2022. PHOTO: REUTERS/Leonhard Foeger
Coronavirus chronicle

Pfizer forecasts $54 bln in 2022 sales of Covid vaccine, pill

FILE PHOTO: An employee holds a vial containing CoronaVac, Sinovac Biotech's vaccine against the coronavirus disease (COVID-19), at Butantan biomedical production center in Sao Paulo, Brazil January 12, 2021. REUTERS/Amanda Perobelli
Coronavirus chronicle

China's Sinovac Covid-19 booster weaker against Omicron - Hong Kong study

 A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. Photo :Reuters
Coronavirus chronicle

Pfizer says Covid-19 pill near 90% effective in final analysis

A vial of the Pfizer vaccine against the coronavirus disease (Covid-19) is seen as medical staff are vaccinated at Sheba Medical Center in Ramat Gan, Israel December 19, 2020. REUTERS/Amir Cohen/File Photo
Coronavirus chronicle

Pfizer booster study lifts mood over Omicron variant

Photo: Collected.
Coronavirus chronicle

Study suggests Pfizer Covid-19 vaccine may only partially protect against Omicron

Vials of coronavirus disease (Covid-19) vaccines of Pfizer-BioNTech and Moderna are seen in the town of Ricany near Prague, Czech Republic, February 25, 2021. REUTERS/David W Cerny/File Photo
Coronavirus chronicle

Mixing Pfizer, AstraZ Covid-19 shots with Moderna gives better immune response: Study

Photo: Collected.
Coronavirus chronicle

Pfizer's Covid-19 vaccine trial data shows long-term efficacy in adolescents

FILE PHOTO: A refrigerated truck leaves the Pfizer plant in Puurs, Belgium December 3, 2020. REUTERS/Yves Herman/File Photo
Coronavirus chronicle

Pfizer to conduct trials of antiviral Covid-19 pill in Russia

A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
Coronavirus chronicle

Canada authorises Pfizer Covid vaccine booster for adults

  • Show More
The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab